Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06460961 · ClinicalTrials.gov registry record · Phase 1

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

A Phase 1 study of Neoplasm Metastasis, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 1
Development phase
168
Enrollment target
7
Study locations

NCT06460961 is a Phase 1 study of Neoplasm Metastasis that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 168 participants, below the 412-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (59% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06460961, a Phase 1 study of Neoplasm Metastasis, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
168 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.

Conditions Studied

Neoplasm Metastasis

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Rescue Medications
  • BIOLOGICAL MK-6837

Study Locations (7)

New Jersey

  • Atlantic Health System Morristown Medical Center ( Site 4001) - Morristown

Oregon

  • Providence Portland Medical Center ( Site 4002) - Portland

Texas

  • South Texas Accelerated Research Therapeutics (START) ( Site 4003) - San Antonio

New South Wales

  • Westmead Hospital ( Site 1002) - Westmead

Victoria

  • The Alfred Hospital ( Site 1001) - Melbourne

Ontario

  • Princess Margaret Cancer Centre ( Site 2001) - Toronto

Other

  • Sheba Medical Center-ONCOLOGY ( Site 3001) - Ramat Gan

Trial Details

FieldValue
Enrollment Target 168 participants
Start Date 2024-07-14
Est. Completion 2027-07-13
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06460961

The ClinicalTrials.gov registry entry for NCT06460961 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (59% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasm Metastasis appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT06460961 reports 7 study locations spanning 7 distinct geographic areas - top geographies include New Jersey, Oregon, Texas.

Frequently Asked Questions

What is clinical trial NCT06460961 about?

NCT06460961 is a clinical study titled "A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)". The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not respond...

What is the current status of trial NCT06460961?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2024-07-14. Estimated completion is 2027-07-13.

What conditions does trial NCT06460961 study?

This clinical trial studies the following conditions: Neoplasm Metastasis.

What interventions are being tested in trial NCT06460961?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Rescue Medications (DRUG), MK-6837 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06460961?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06460961 being conducted?

This trial has 7 study locations across New Jersey, Oregon, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasm Metastasis

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.